vimarsana.com

Latest Breaking News On - Charles eden - Page 1 : vimarsana.com

SYMRISE AG : UBS gives a Buy rating - MarketScreener

Analyst Charles Eden from UBS research considers the stock attractive and recommends it with a Buy rating. The target price is unchanged at EUR 131.

GIVAUDAN AG : Receives a Sell rating from UBS -April 11, 2024 at 04:50 am EDT

In a research note published by Charles Eden, UBS advises its customers to Sell the stock. The target price is unchanged and still at CHF 3200.

SYMRISE AG : UBS reiterates its Buy rating -April 03, 2024 at 06:45 am EDT

In his latest research note, analyst Charles Eden confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price has been raised from EUR 120 to EUR 131.

GIVAUDAN AG : Receives a Sell rating from UBS -January 26, 2024 at 02:23 am EST

In a research note published by Charles Eden, UBS advises its customers to Sell the stock. The target price is being increased from CHF 2860 to CHF 2950.

GIVAUDAN AG : UBS remains a Sell rating -January 25, 2024 at 03:33 am EST

Charles Eden from UBS retains his negative opinion on the stock with a Sell rating. The target price remains set at CHF 2860.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.